Casperome® overview

Scientific support

CASPEROME®, highly standardized in boswellic acids, is formulated with Phytosome® technology to achieve optimized absorption of the actives.
In combination with sodium hyaluronate, collagene and glucosamine, CASPEROME® has been shown to be supportive against elbow and tendon challenges;2,3

In a registry study, CASPEROME® has been shown – compared to the best available treatments – to significantly
alleviate all Irritable Bowel Syndrome symptoms.14

Furthermore in literature is is reported that:
KBA and AKBA are selective 5-lipoxygenase inhibitor and then capable to manage the inflammatory response function through leukotriene inhibition.4 But recent findings have shifted the focus on β-boswellic acid, the major triterpenoid from the gum-resin, and its capability to modulate the inflammatory response enzymes cathepsin (catG)5 and microsomal prostglandin E synthase (mPGES)-1,6 suggesting that β-boswellic acid plays a major role while the whole bouquet of triterpenoid acids is important for the beneficial effects of boswellia.

Boswellia extracts have been demonstrated to be useful for bowel related inflammatory responses,7-10 and to improve physical function in subjects with joint and tendon challenges.11

The bioavailability of boswellic acids from CASPEROME® is greatly optimized both at the plasma and at the tissue level.12,13

 References
1 Buechele B. et al. J Chromatogr B 2003; 795: 355-62
2 Lazzaro F. GIOT 2014;40:141-150
3 Lazzaro F., Loiero M. GIOT 2014;40:249-257
4 Safayhi H. et al. J Pharmacol Exp Ther 1992; 261: 1143-6
5 Tausch L. et al. J Immunol 2009; 183: 3433-42
6 Fahmi H. Curr Opin Rheumatol 2004; 16 (5): 623-7
7 Gupta I. et al. Eur J Med Res 1997; 2 (1): 37-43
8 Gupta I. et al. Planta Med 2001; 67 (5): 391-5
9 Khajuria A. et al. Vaccine 2007; 25 (23): 4586-94
10 Gerhardt H. et al. Z Gastroenterol 2001; 39: 11-7
11 Sengupta K. et al. Arthritis Res Ther 2008; 10 (4): R85
12 Hüsch J. et al. Fitoterapia 84 (2013) 89-98
13 Gerbeth K. et al. Fitoterapia 84 (2013) 99-106
14 Belcaro G. et al. Eur Rev Med Pharmacol Sci 21(9), 2249-54. 5 2017